On March 17, 2025, IceCure Medical Ltd. announced it received a Notice of Allowance for its invention titled 'Cryogenic System Connector' from the China National Intellectual Property Administration. This latest intellectual property win rounds out protection for the novel cryogenic pump in major global markets, following previous grants for the same patent in the U.S., Europe, and Japan. The cryogenic pump is a key component for IceCure's next-generation cryoablation systems.
The novel cryogenic pump is submersible in liquid nitrogen (LN2), operates in a closed circuit, and enables precise temperature control of the cryoprobe. It is designed to improve the cooling rate during procedures and allows for multiple or longer-duration procedures without the need to refill LN2. This innovation facilitates the development of new cryoablation systems with a smaller footprint and a broader range of thinner cryoprobes and catheters, expanding clinical applications.
IceCure's CEO, Eyal Shamir, stated that with over 50 granted patents, IceCure is a global leader in LN2-based cryoablation. This intellectual property, combined with growing regulatory approvals and commercial traction, supports the company's goal of de-escalating surgery across various indications through safe and effective cryoablation procedures.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.